We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
Read MoreHide Full Article
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.
Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.
Per the company, Journavx has the potential to transform the treatment paradigm of acute pain. Pain is an area with limited treatment options, mostly highly addictive opioid-based medications.
Vertex believes Journavx, a non-opioid drug, is an effective and well-tolerated medicine for use in all types of moderate-to-severe acute pain.
Shares of VRTX were up more than 8% in after-hours trading on Jan. 30 following the news announcement. The stock was also up in pre-market trading on Jan. 31.
The stock has risen 1.2% in the past year against the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
The FDA accepted the new drug application (“NDA”) for Journavx in July 2024.
VRTX Developing Suzetrigine for Other Indications
Besides acute pain, suzetrigine is also being developed for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy (“LSR”).
The company’s stock nosedived in December 2024, when it announced data from a phase II study on suzetrigine, for treating painful LSR, a form of peripheral neuropathic pain.
Data from the study showed that treatment with suzetrigine led to a statistically significant and clinically meaningful within-group reduction in pain from baseline with a mean change in numeric pain rating scale of -2.02 at week 12, thereby meeting the primary endpoint. The placebo arm demonstrated a reduction of -1.98 points, indicating not much difference between the two groups.
Overall, investors were not impressed with the data as it showed largely undifferentiated pain reduction on treatment with suzetrigine compared to the placebo arm.
Despite the unimpressive data in the phase II study, management decided to proceed with the phase III study in this indication, which was considered a risky decision.
Vertex initiated a pivotal phase III program of suzetrigine in diabetic peripheral neuropathy, a form of peripheral neuropathic pain caused by damage to nerves, in the third quarter of 2024.
It remains to be seen how Journavx performs in the acute pain indication, especially after disappointing data from the LSR study.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.70 for 2025. In the past year, shares of CSTL have increased 21.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 25.3%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 27.6%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.
Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.
Per the company, Journavx has the potential to transform the treatment paradigm of acute pain. Pain is an area with limited treatment options, mostly highly addictive opioid-based medications.
Vertex believes Journavx, a non-opioid drug, is an effective and well-tolerated medicine for use in all types of moderate-to-severe acute pain.
Shares of VRTX were up more than 8% in after-hours trading on Jan. 30 following the news announcement. The stock was also up in pre-market trading on Jan. 31.
The stock has risen 1.2% in the past year against the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
The FDA accepted the new drug application (“NDA”) for Journavx in July 2024.
VRTX Developing Suzetrigine for Other Indications
Besides acute pain, suzetrigine is also being developed for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy (“LSR”).
The company’s stock nosedived in December 2024, when it announced data from a phase II study on suzetrigine, for treating painful LSR, a form of peripheral neuropathic pain.
Data from the study showed that treatment with suzetrigine led to a statistically significant and clinically meaningful within-group reduction in pain from baseline with a mean change in numeric pain rating scale of -2.02 at week 12, thereby meeting the primary endpoint. The placebo arm demonstrated a reduction of -1.98 points, indicating not much difference between the two groups.
Overall, investors were not impressed with the data as it showed largely undifferentiated pain reduction on treatment with suzetrigine compared to the placebo arm.
Despite the unimpressive data in the phase II study, management decided to proceed with the phase III study in this indication, which was considered a risky decision.
Vertex initiated a pivotal phase III program of suzetrigine in diabetic peripheral neuropathy, a form of peripheral neuropathic pain caused by damage to nerves, in the third quarter of 2024.
It remains to be seen how Journavx performs in the acute pain indication, especially after disappointing data from the LSR study.
VRTX's Zacks Rank & Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Castle Biosciences, Inc. (CSTL - Free Report) , Harmony Biosciences Holdings, Inc. (HRMY - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.70 for 2025. In the past year, shares of CSTL have increased 21.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 25.3%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 27.6%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.